» Authors » Ulrich Speck

Ulrich Speck

Explore the profile of Ulrich Speck including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 56
Citations 1362
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
von Gottberg P, Cimpoca A, Wendl C, Cohen J, Speck U, Henkes H
Rev Cardiovasc Med . 2024 Jul; 23(4):128. PMID: 39076219
Background: Drug-coated balloons (DCB) are an established tool in the prevention and treatment of coronary and peripheral artery restenosis. The underlying effects of restenosis resemble those in the neurovascular field,...
2.
Haase T, Speck U, Bienek S, Lochel M, Brunacci N, Gemeinhardt O, et al.
Front Biosci (Landmark Ed) . 2022 Nov; 27(10):283. PMID: 36336862
Background: Although controversially discussed, paclitaxel is the only clinically proven drug that inhibits restenosis when released from drug-coated balloons (DCBs). Limus drugs are currently being explored as alternatives. The aim...
3.
Gemeinhardt O, Haase T, Schnorr B, Xie J, Lochel M, Schutt D, et al.
Cardiovasc Intervent Radiol . 2022 Sep; 45(12):1822-1831. PMID: 36109387
Purpose: Clinical data indicate that the drug density on drug-coated balloons (DCBs) might have a role on treatment effect and durability. The aim of the current study was to investigate...
4.
Gemeinhardt O, Schnorr B, Speck U, Scheller B
PLoS One . 2021 Oct; 16(10):e0259106. PMID: 34714843
Background: Drug coated balloons (DCB) with paclitaxel (Ptx) dose of 2-3.5 μg/mm2 balloon surface inhibit restenosis with different effectiveness and duration of success. A clinical dose finding study is not...
5.
Bettink S, Lochel M, Peters D, Haider W, Speck U, Scheller B
Int J Cardiol . 2021 Jan; 331:46-56. PMID: 33418002
Background: Local administration of growth-inhibiting substances such as paclitaxel or sirolimus could reduce the risk of restenosis. In the drug coated balloon (DCB) technology the coating and the applied dose...
6.
Tepe G, Schroeder H, Albrecht T, Reimer P, Diehm N, Baeriswyl J, et al.
J Endovasc Ther . 2020 Feb; 27(2):276-286. PMID: 32096451
To investigate the efficacy and sustainability of drug-coated balloon (DCB) treatment of femoropopliteal in-stent restenosis (ISR). An investigator-initiated, prospective, multicenter, 1:1 randomized study enrolled 88 patients for treatment of ISR...
7.
Albrecht T, Ukrow A, Werk M, Tepe G, Zeller T, Meyer D, et al.
Cardiovasc Intervent Radiol . 2019 Mar; 42(7):1055. PMID: 30863966
In their recently published pooled analysis of four drug-coated balloon (DCB) studies, which focused on the impact of patient and lesion characteristics on LLL at 6 months (Albrecht T et...
8.
Albrecht T, Ukrow A, Werk M, Tepe G, Zeller T, Meyer D, et al.
Cardiovasc Intervent Radiol . 2018 Dec; 42(4):495-504. PMID: 30539236
Objectives: The principal objective of this pooled analysis was to investigate various patient and lesion characteristics on late lumen loss (LLL) after drug-coated balloon (DCB) angioplasty. Background: Four randomized controlled...
9.
Speck U, Hackel A, Schellenberger E, Kamann S, Lochel M, Clever Y, et al.
Cardiovasc Intervent Radiol . 2018 Jul; 41(10):1599-1610. PMID: 29968090
Purpose: To experimentally investigate a new homogenously paclitaxel/resveratrol-coated balloon catheter in terms of transport of the coating to the treated tissue and local effects including histology and functional tests. Methods:...
10.
Cremers B, Binyamin G, Clever Y, Seifert P, Konstantino E, Kelsch B, et al.
EuroIntervention . 2016 Dec; 12(17):2140-2147. PMID: 27973329
Aims: The study aimed to assess drug adherence, transfer to the vessel wall, tolerance and efficacy of a constrained angioplasty balloon coated with an excipient-enhanced paclitaxel coating (Chocolate coated balloon...